{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:35:26Z","timestamp":1793784926421,"version":"4.6.1"},"reference-count":153,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Therapeutic advances across the gynecologic cancer continuum have resulted in improvements in patient care and outcomes over the past decade, yet challenges remain. In ovarian cancer, the evolution of poly (ADP-ribose) polymerase (PARP) inhibitor therapy has resulted in marked benefit for patients with BRCA-mutated cancers but has also unmasked the need for new therapies in patients whose cancers are proficient in homologous recombination and lack vulnerability to PARP inhibitors, as well as for those patients whose cancers progress on PARP inhibitors. In endometrial cancer, immune checkpoint inhibitors (ICIs) have improved outcomes for patients receiving first-line therapy for advanced or recurrent disease when combined with standard-of-care chemotherapy. However, there remains uncertainty around which patients are most likely to benefit from the addition of immunotherapy, and treatment beyond first-line therapy remains an area of high unmet need. Similarly, ICIs added to chemotherapy for recurrent or metastatic cervical cancer or to chemoradiation for high-risk locally advanced cervical cancers has resulted in improved outcomes, but treatment options beyond this remain limited. Across gynecologic cancers, antibody-drug conjugates (ADCs) hold the promise for further improvement in patient outcomes. A prime example is the demonstrated benefit of mirvetuximab soravtansine over other standard chemotherapy options in folate receptor alpha\u2013high platinum-resistant ovarian cancer. Maximizing such potential will require developing a deeper understanding of relationships between ADC target expression and activity, mechanisms of resistance, and potential approaches to sequencing. Beyond ADCs, additional therapies, including those targeting DNA damage response, remain in development.<\/jats:p>","DOI":"10.1200\/edbk-25-473114","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T19:59:22Z","timestamp":1749499162000},"source":"Crossref","is-referenced-by-count":15,"title":["State of the Art: Therapies Now and Around the Corner for Gynecologic Cancers"],"prefix":"10.1200","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-0718","authenticated-orcid":true,"given":"Kathleen N.","family":"Moore","sequence":"first","affiliation":[{"name":"Stephenson Cancer Center at OU Health, University of Oklahoma, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce F.","family":"Liu","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Milan, Italy"},{"name":"Humanitas San Pio X, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24149"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt333"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21456"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01009"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.1684"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01549"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.005"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2241"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01003"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.022"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.0505"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.08.004"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30279-6"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30142-X"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.06.011"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.5550"},{"key":"e_1_3_3_24_2","first-page":"A21","article-title":"#528 Efficacy of subsequent chemotherapy followed by PARP inhibitor maintenance in patients with advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-Ov25 trial","volume":"33","author":"Marth C","year":"2023","unstructured":"Marth C, Mouret-Reynier M-A, Lorusso D, et al: #528 Efficacy of subsequent chemotherapy followed by PARP inhibitor maintenance in patients with advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-Ov25 trial. Int J Gynecol Cancer 33:A21, 2023","journal-title":"Int J Gynecol Cancer"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3110"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1408"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00342-9"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00306"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.06.018"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103550"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2269"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101704"},{"key":"e_1_3_3_35_2","unstructured":"GSK: GSK announces FIRST trial met its primary endpoint of progression free survival in first line advanced ovarian cancer. 2024. https:\/\/www.gsk.com\/media\/11730\/first-press-release-final-201224.pdf"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00529"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00668"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00216-3"},{"key":"e_1_3_3_39_2","first-page":"A4","article-title":"A randomized, phase II\/III study of pegylated-liposomal-doxorubicin and atezolizumab versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)","volume":"33","author":"O'Cearbhaill RE","year":"2023","unstructured":"O'Cearbhaill RE, Sill MW, Duong H, et al: A randomized, phase II\/III study of pegylated-liposomal-doxorubicin and atezolizumab versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009). Int J Gynecol Cancer 33:A4, 2023","journal-title":"Int J Gynecol Cancer"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5501"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.1007"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010143"},{"key":"e_1_3_3_43_2","volume-title":"Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination with Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer","year":"2021","unstructured":"Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination with Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer. 2021 https:\/\/investor.alkermes.com\/news-releases\/news-release-details\/alkermes-receives-fda-fast-track-designation-nemvaleukin-alfa-0"},{"key":"e_1_3_3_44_2","first-page":"A211","article-title":"347 clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial","volume":"8","author":"Winer I","year":"2020","unstructured":"Winer I, Gilbert L, Vaishampayan U, et al: 347 clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial. J Immunother Cancer 8:A211-A212, 2020","journal-title":"J Immunother Cancer"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100821"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1933"},{"key":"e_1_3_3_47_2","unstructured":"Gaillard S Guo R Finkelstein K et al: Safety and preliminary efficacy of puxitatug samrotecan (AZD8205) in patients with endometrial cancer: A first-in-human phase 1\/2a study. Presented at The 2025 Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer; March 2025 Seattle WA"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1924"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3082"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1920"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.781"},{"key":"e_1_3_3_52_2","doi-asserted-by":"crossref","unstructured":"Martin L Konner J O'Malley D et al: Phase I expansion study of mirvetuximab soravtansine a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC) in patients with endometrial cancer. Presented at the European Society of Gynaecological Oncology; Nopvember 2017; Vienna Austria","DOI":"10.26226\/morressier.59ba7298d462b80296ca210c"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.782"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.820"},{"key":"e_1_3_3_56_2","volume-title":"BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323\/DB-1303 in Endometrial Cancer","year":"2023","unstructured":"BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323\/DB-1303 in Endometrial Cancer. 2023. https:\/\/investors.biontech.de\/news-releases\/news-release-details\/biontech-and-dualitybio-receive-fda-breakthrough-therapy?utm_source=chatgpt.com"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5528"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.039"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.776"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02767"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.038"},{"key":"e_1_3_3_62_2","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1016\/j.annonc.2024.08.777","article-title":"715MO\u2014Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study","volume":"35","author":"Wang DWK","year":"2024","unstructured":"Wang DWK, Wang K, An R, et al: 715MO\u2014Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study. Ann Oncol 35:S548-S595, 2024","journal-title":"Ann Oncol"},{"key":"e_1_3_3_63_2","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1016\/j.annonc.2024.08.778","article-title":"716MO\u2014Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer","volume":"35","author":"Wang J","year":"2024","unstructured":"Wang J, An R, Huang Y, et al: 716MO\u2014Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer. Ann Oncol 35:S548-S549, 2024","journal-title":"Ann Oncol"},{"key":"e_1_3_3_64_2","volume-title":"Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial","author":"Daiichi-Sankyo","year":"2023","unstructured":"Daiichi-Sankyo: Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial. 2023. https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202310\/20231022_E2.pdf"},{"key":"e_1_3_3_65_2","unstructured":"Lee EK Yeku O Winer I et al: Rinatabart sesutecan (Rina-S) for patients with advanced ovarian cancer: Results from dose expansion cohort B1 of a phase 1\/2 study. Presented at the 2025 Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer; March 2025; Seattle WA"},{"key":"e_1_3_3_66_2","doi-asserted-by":"crossref","unstructured":"Lee J-Y Oaknin A Lorusso D et al: Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: Results from the dose-optimization stage of the REFR\u03b1ME-O1 (GOG-3086 ENGOT-79OV and APGOT-OV9) phase 2\/3 study. Presented at the 2025 Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer; March 2025: Seattle WA","DOI":"10.1136\/ijgc-2024-IGCS.612"},{"key":"e_1_3_3_67_2","unstructured":"Sutro Biopharma announces strategic portfolio review resulting in the prioritization of its next-generation ADC pipeline. 2025. https:\/\/ir.sutrobio.com\/news-events\/news-releases\/detail\/209\/sutro-biopharma-announces-strategic-portfolio-review-resulting-in-the-prioritization-of-its-next-generation-adc-pipeline"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.07.017"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.01.020"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.011"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.826"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32554-X"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00830"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.08.024"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2444"},{"key":"e_1_3_3_76_2","article-title":"Ceralasertib-mediated ATR inhibition combined with olaparib in advanced cancers harboring DNA damage response and repair alterations (olaparib combinations)","author":"Mahdi H","unstructured":"Mahdi H, Hafez N, Doroshow D, et al: Ceralasertib-mediated ATR inhibition combined with olaparib in advanced cancers harboring DNA damage response and repair alterations (olaparib combinations). JCO Precis Oncol 10.1200\/PO.20.00439","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5510"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0409"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-4007"},{"key":"e_1_3_3_80_2","article-title":"First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations","volume":"42","author":"Yap TA","year":"2024","unstructured":"Yap TA, Lakhani NJ, Patnaik A, et al: First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations. J Clin Oncol 42, 2024 (suppl 16; abstr 3005)","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14184"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00203-x"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT169"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114661"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12113"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.03.034"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.05.018"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.01.025"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.5966"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0953"},{"key":"e_1_3_3_93_2","volume-title":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Uterine Neoplasms Version 3","year":"2025","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Uterine Neoplasms Version 3. 2025"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302312"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216334"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.546"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02132"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00334-6"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1919"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-IGCS.5"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2242"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.12.030"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.797"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.016"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02906"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105"},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01874"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01021"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002255"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4515"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108330"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02152"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13883"},{"key":"e_1_3_3_114_2","unstructured":"Reference deleted"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.07.002"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00628"},{"key":"e_1_3_3_117_2","first-page":"OF1","article-title":"A phase II study of fulvestrant plus abemaciclib in hormone receptor-positive advanced or recurrent endometrial cancer","author":"Green AK","year":"2024","unstructured":"Green AK, Zhou Q, Iasonos A, et al: A phase II study of fulvestrant plus abemaciclib in hormone receptor-positive advanced or recurrent endometrial cancer. Clin Cancer Res OF1-OF9, 2024. doi: 10.1158\/1078-0432.CCR-24-1999","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.12.003"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1222577110"},{"key":"e_1_3_3_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.010"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03167"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.06.512"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.2016.008151"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004429"},{"key":"e_1_3_3_125_2","article-title":"Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline","author":"Chuang LT","unstructured":"Chuang LT, Temin S, Camacho R, et al: Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline. JCO Glob Oncol 10.1200\/JGO.2016.003954","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_3_126_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.12611"},{"key":"e_1_3_3_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2020.04.002"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30753-1"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1339"},{"key":"e_1_3_3_130_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904153401501"},{"key":"e_1_3_3_131_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904153401502"},{"key":"e_1_3_3_132_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904153401503"},{"key":"e_1_3_3_133_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.8.1606"},{"key":"e_1_3_3_134_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4368"},{"key":"e_1_3_3_135_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02852"},{"key":"e_1_3_3_136_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.9985"},{"key":"e_1_3_3_137_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103638"},{"key":"e_1_3_3_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01438-7"},{"key":"e_1_3_3_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00479-5"},{"key":"e_1_3_3_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00317-9"},{"key":"e_1_3_3_141_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5367"},{"key":"e_1_3_3_142_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8909"},{"key":"e_1_3_3_143_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31607-0"},{"key":"e_1_3_3_144_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.08.026"},{"key":"e_1_3_3_145_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.08.018"},{"key":"e_1_3_3_146_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00739"},{"key":"e_1_3_3_147_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5471"},{"key":"e_1_3_3_148_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01265"},{"key":"e_1_3_3_149_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115146"},{"key":"e_1_3_3_150_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00914"},{"key":"e_1_3_3_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02405-4"},{"key":"e_1_3_3_152_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02135-4"},{"key":"e_1_3_3_153_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313811"},{"key":"e_1_3_3_154_2","volume-title":"RemeGen Presents Oral Presentation on Evaluation of its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024","year":"2024","unstructured":"RemeGen Presents Oral Presentation on Evaluation of its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024. 2024. https:\/\/www.prnewswire.com\/news-releases\/remegen-presents-oral-presentation-on-evaluation-of-its-proprietary-disitamab-vedotin-rc48-for-cervical-cancer-at-esgo-2024-302084877.html"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-25-473114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T19:59:28Z","timestamp":1749499168000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-25-473114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":153,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/EDBK-25-473114"],"URL":"https:\/\/doi.org\/10.1200\/edbk-25-473114","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"e473114"}}